Hyperlipidemias

Clinics in Dermatology

Volumn 14, Issue 4, 1996, Pages 367-374

  Russo, Glenn G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C2; APOPROTEIN; CHOLESTEROL; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIPOPROTEIN X; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALCOHOL CONSUMPTION; CHOLESTASIS; HISTOPATHOLOGY; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LIPID METABOLISM; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW; XANTHOMA;

EID: 0030575327     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0738-081X(96)00066-1     Document Type: Article

References (45)

1. 1. Erkelens DW. Normal and abnormal metabolism of lipoprotein. Curr Probl Dermatol 1991;20:45-33.
2. 2. Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol 1985;13:1-30.
3. 3. Douste-Blagy P, Maacel YL, Cohen L, et al. Increased frequency of Apo-E-ND phenotype and apobetalipoproteinemia in normolipidemic subjects and xanthelasmas of the eyelids. Ann Intern Med 1982;96:164-9.
4. 4. Moriyama K, Saraki J, Matsunega A, et al. Apolipoprotein E1 lys-146-Glu with type III hyperlipoproteinemia. Biochim Biophys Acta 1992;1128:58-64.
5. 5. Scott PJ, Winterboum CC. Low-density lipoprotein accumulation in actively growing xanthomas. J Atherosch Res 1967;7:207-23.
6. 6. Goldstein JL, Ho YK, Baru SK, et al. Binding site on macrophages mediate uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
7. 7. Suits SG, Chait A, Aviram M, et al. Phagocytosis of aggregated lipoprotein by macrophages: Low-density lipoprotein receptor-dependent foam cell formation. Proc Natl Acad Sci USA 1989;86:2713-7.
8. 8. Aviram M. Low-density lipoprotein and scavanager receptor activities are modulated by secretory products derived from cells of the arterial wall. Metabolism 1989;38: 445-9.
9. 9. Esterbauer H, Dieber-Rotheneder M, Waeg G, et al. Biochemical, structural, and functional properties of oxidized lower-density lipoprotein. Clin Res Toxicol 1990;3:77-92.
10. 10. Hu CH, Ellefson RD, Winkelman RK. Lipid synthesis in cutaneous xanthoma. J Invest Dermatol 1982;79:80-5.
11. 11. Feiwel M. Xanthomas in cryoglobulinemia and other paraproteinemias with report of a case. Br J Dermatol 1968;80:719-29.
12. 12. Elias P, Goldsmith LA. Intertriginous xanthoma in type II hyperbetalipoproteinemia. Arch Dermatol 1973;107: 761-2.
13. 13. Nigale V, Khopkar U, Trasi S, et al. Flexual planar xanthomas: Report of four cases. Cutis 1995;56:291-2.
14. 14. Polano MD. Xanthomatosis and hyperlipoproteinemia. Dermatologica 1974;149:1-9.
15. 15. Cruz PD, East C, Bertresser PR. Dermal, subcutaneous and tendon xanthomas: Diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 1988;19:95-111.
16. 16. Gattereau A, Davignon J, Langelier M, et al. An improved radiological method for the evaluation of Achilles tendon xanthomatosis. Can Med Assoc J 1973;108:39-43.
17. 17. Bhattacharyya AK, Conner WE. Beta-sitosterolemia and xanthomatosis. J Clin Invest 1974;53:1033-43.
18. 18. Matsuo I, Yoshino K, Ozawa A, et al. Phytosterolemia and type II hyperlipoproteinemia with tuberous xanthomas. J Am Acad Dermatol 1981;4:47-9.
19. 19. Philippart M, van Bogaert L. Cholestenandosis (cerebrotendinous xanthomatosis). Arch Neurol 1969;21:604-10.
20. 20. Braun-Falco O. Origin, structure, and functions of the xanthoma cell. Nutr Metab 1973;15:68-88.
21. 21. Frederickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-44, 94-103,148-56, 215-25, and 273-81.
22. 22. Seymour CA. Xanthomas and abnormalities of lipid metabolism and storage. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of Dermatology, 5th ed. London: Blackwell Scientific Publications, 1992;2314-23.
23. 23. Havel RJ, Gordon RS Jr. Idiopathic hyperlipidemia: Metabolic studies in an affected family. J Clin Invest 1960;39: 1777-90.
24. 24. Levy RI, Rifkind BM. Diagnosis and management of hyperlipoproteinemia in infants and children. Am J Cardiol 1973;31:547-56.
25. 25. Zwidemia GD. The association of lipid abnormality and acute pancreatitis. J Iri Coll Physicians Surg 1973;2:65-71.
26. 26. Utermann G, Hess M, Steinmetz A. Polymorphism of lipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977;269:604-7.
27. 27. Verner BR, et al. Familial dysbetalipoproteinemia: A genetically heterogenous disease caused by mutations of the ligand apolipoprotein E. J Invest Dermatol 1992;98:58s.
28. 28. Bierman EL, Porte D Jr. Carbohydrate intolerance and lipemia. Ann Intern Med 1968;68:926-33.
29. 29. Havel RJ. Pathogenesis, differentiation, and management of hypertriglyceridemia. Adv Intern Med 1969;15:117-54.
30. 30. Fallet RW, Glueck CJ. Familial and acquired type V hyperlipoproteinemia. Atherosclesosis 1976;23:41-62.
31. 31. Goldstein JL, Schrott HG, Hazard WR, et al. Hyperlipidemias in coronary artery disease: Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined with hyperlipidemia. J Clin Invest 1973;52:1544-68.
32. 32. Utermann G. Apolipoprotein, polymorphism, and multi-factorial hyperlipidemia. J Inter Dis 1988;11(Suppl):74-86.
33. 33. Miwa N, Kazzaki T. The Koebner phenomenon in eruptive xanthomas. J Dermatol 1992;19(1):48-50.
34. 34. Miller DM, Brodell RT. Eruptive xanthomatosis with linear koebnerization. J Am Acad Dermatol 1995;33:834-5.
35. 35. Klemp P, Halland AM, Majoos FL, et al. Musculoskeletal manifestations in hyperlipidaemia: A controlled study. Ann Rheum Dis 1993;52:44-8.
36. 36. Rosenman RH, Brand RJ, Sholtz R, et al. Relationship of corneal arcus to cardiovascular risk factors and the incidence of coronary disease. N Engl J Med 1924;291:1322-4.
37. 37. Bagdade JC, Porte D, Bierman EL. Diabetic lipemia: A form of acquired fat-induced lipemia. N Engl J Med 1967; 276:427-33.
38. 38. Hazzard WR, Spiger MJ, Bagdade JC, et al. Studies on the mechanism of increased plasma triglyceride levels induced by oral contraceptives. N Engl J Med 1969;280: 471-4.
39. 39. Molitch ME, Oill P, Odell WD. Massive hyperlipidemia during estrogen therapy. JAMA 1974;227:522-5.
40. 40. Dicken CH, Connolly SM. Eruptive xanthomas associated with isotretinoin (13-cis-retinoic acid) Arch Dermatol 1980;116:951-2.
41. 41. Newmark SR, Anderson CF, Donadio JV, et al. Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 1975;50: 359-64.
42. 42. Verschoor L, Baggen RG, Jansen H, et al. Different causes for hypertriglyceridemia in male and female patients with chronic renal failure? J Clin Endocrinol Metab 1983;56: 592-4.
43. 43. O'Hara PD, Porte D, Williams RH, The effect of diet and thyroxine on plasma lipids in myxedema. Metabolism 1966;15:123-34.
44. 44. Feiwel M. Xanthomatosis in cryoglobulinemia and other paraproteinemias with report of a case. Br J Dermatol 1968;80:719-29.
45. 45. Lynch PJ, Winkelman RK. Generalized plane xanthoma and systemic disease. Arch Dermatol 1966;93:639-46.